To evaluate anti-cytokine therapy at distinct disease phases, we induced anti-MPO autoimmunity in mice through MPO immunization and triggered GN using anti-glomerular basement membrane (GBM) globulin at early (day 20) and late (days 32 and 38) stages. The gene discussed is MPO; the disease is ganglioneuroma.